Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antitumor vaccination using peptide based vaccines.

L Eisenbach1, E Bar-Haim, K El-Shami

  • 1Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel. lea.eisenbach@wezmann.ac.il

Immunology Letters
|September 21, 2000
PubMed
Summary

Cytotoxic T Lymphocytes (CTLs) target tumors by recognizing peptides from Tumor Associated Antigens (TAAs) presented by MHC class I molecules. This review covers TAA identification, peptide characteristics, and the development of antitumor vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103<sup>+</sup> dendritic cell populations following respiratory infection.

Mucosal immunology·2017
Same author

Amplification of the expression of major histocompatibility class-I antigens by inducers of differentiation and gamma interferon in murine and human solid tumor-cell lines.

International journal of oncology·2011
Same author

Immunotherapy for myeloid leukemias: current status and future directions.

Leukemia·2008
Same author

'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

British journal of cancer·2007
Same author

O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

Clinical and experimental immunology·2005
Same author

Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

Vaccine·2005

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cytotoxic T Lymphocytes (CTLs) are crucial for tumor rejection.
  • CTL recognition relies on Major Histocompatibility Complex (MHC) class I presenting peptides.
  • Tumor Associated Antigens (TAAs) are a source of tumor-specific peptides.

Purpose of the Study:

  • To review methods for identifying TAAs and their associated peptides.
  • To describe the characteristics of TAA-derived peptides.
  • To discuss the development of antitumor vaccines based on TAAs.

Main Methods:

  • Literature review of TAA and peptide identification techniques.
  • Analysis of published data on TAA peptide properties.
  • Synthesis of information on antitumor vaccine strategies.

Related Experiment Videos

Main Results:

  • Numerous TAAs have been identified in human and murine tumors.
  • TAA peptides serve as targets for CTL-mediated tumor rejection.
  • Understanding TAA peptides is key to designing effective vaccines.

Conclusions:

  • TAA identification and characterization are advancing tumor immunology.
  • TAA-derived peptides offer promising targets for cancer immunotherapy.
  • Antitumor vaccines leveraging TAAs hold potential for cancer treatment.